webinar

Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption

📅 Add to Calendar! |  🎥 Join Webinar on Zoom The arrival of GLP-1 medications has been described as one of the most important healthcare innovations in recent years. In this webinar, Jasmin Moshfegh (Imperial College Business School) will present large-scale quasi-experimental evidence on the real-world impacts of GLP-1 adoption. Using comprehensive Veterans Health Administration […]

Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption Read More »

Where is Gender in Health Economics?

Presenters: Veloshnee Govender, Rajalakshmi RamPrakash, Michelle Remme,  Lavanya Vijayasingham   In this webinar we argue that gender equity has been relatively neglected in the field of health economics. This neglect has been to the detriment of building theory, research and health policy and programme implementation. We will illustrate our argument through specific application of gender

Where is Gender in Health Economics? Read More »

Prioritising genomic medicine: reflections on the role of health economics for changing policy and clinical practice

Genomic medicine is rapidly changing the healthcare paradigm for multiple conditions, including cancer and rare diseases. With governments around the world increasingly investing in genomics research and implementation into clinical practice, and with the health economics evidence base on genomic medicine expanding, it is important to reflect on the role of health economics to change

Prioritising genomic medicine: reflections on the role of health economics for changing policy and clinical practice Read More »

Preferences for Adjuvant Immunotherapy in Resected Stage III Melanoma

Presenter: Ann Livingstone, University of Sydney Ann was recently awarded her PhD. She has a keen interest in patient preferences in trial-based and modelled economic evaluation. In addition, she works as an evaluator for the Australian Medical Services Advisory Committee, reviewing and critiquing evidence to inform government policy decision-making regarding health technologies. Adjuvant immunotherapy has

Preferences for Adjuvant Immunotherapy in Resected Stage III Melanoma Read More »